revenu beat hiv letairi
report revenu beat consensu non-gaap ep
miss consensu strength top-lin driven hiv sale
lack gener letairi competit ep neg impact opex
guid product sale compar consensu non-
 sg expens guid rang
respect assum nash launch cost pend success phase trial
reiter neutral rate increas po base non-
gaap ep vs previous increas given potenti return revenu
growth exclud favor impact delay letairi lower eros
ex-u hiv gener guidanc suggest product sale grow level
hiv beat led biktarvi genvoya truvada
hiv sale top consensu mainli driven truvada prep
indic biktarvi genvoya well season inventori purchas favor
payer mix continu see strong momentum biktarvi despit price eros
hiv franchis hcv sale miss consensu go forward
expect stabil hcv market guid eros
phase result selonsertib inhibitor nash patient
expect respect fibrosi benefit phase trial
appear interest think result taken grain salt given
small size trial lack placebo though simtuzumab shown
ineffect said placebo-adjust fibrosi benefit demonstr
could ralli given commerci opportun nash low expect
remain focus await new ceo strategi
reiter focu partnership follow dividend share
repurchas balanc sheet investor may wonder whether
would seek sizeabl deal new ceo daniel oday take offic march
think he like take time learn compani busi
formul strategi
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biopharmaceut compani
discov develop commerci
therapi treatment hiv/aid liver
diseas cancer inflamm recent
acquisit kite allow entri car-t
space indic renew focu oncolog
rate neutral believ price
trend patient volum declin
hcv market although hiv franchis
rel healthi hand recent
acquisit kite allow growth
price object base non-gaap ep estim line
peer believ multipl justifi given hcv sale enter steadi
upsid risk price object faster-than-expect growth product
sale less-than-anticip pressur price weaker-than-expect
competit greater faster progress pipelin
downsid risk price object slower-than-expect growth product
sale greater-than-anticip pressur price slower progress
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
